![img](/media/00dhasd3/shape-bg.png)
About Us
Company Profile
Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio or the Company; stock code: 2179.HK) is an innovative vaccine company propelled by internally developed technologies. Committed to our mission of " Protect human health with best-in-class vaccines", we have cultivated a robust portfolio of vaccine products with exclusive rights, addressing the substantial unmet needs in the realm of high-impact infectious diseases. Over the course of more than two decades, Recbio has meticulously built three pioneering platforms: a novel adjuvant platform, a protein engineering platform, and an immunological evaluation platform, making us one of the few global companies capable of both developing and manufacturing the complete range of novel adjuvants.
Leveraging the close integration of our three platforms, we are consistently creating promising vaccine candidates. Fueled by these innovative platforms, the Company has forged a high-value portfolio of innovative vaccines, encompassing over ten potential blockbuster varieties. These encompass areas such as cervical cancer, shingles, RSV infection, and other prevalent high-burden diseases, and have emerged as leading products in terms of development and clinical progress in China.
Having been honed and refined over the course of a decade, Recbio is poised to reap the benefits as several products are nearing commercialization.
Leadership
![img](/media/nfpf4egl/ellipse-7.png)
Founder, Chairman of the Board and CEO
![img](/media/nfpf4egl/ellipse-7.png)
Founder, Chairman of the Board and CEO
Dr. Liu Yong is responsible for the overall management of Recbio business strategy, corporate development and R&D.
Dr. Liu holds a Ph.D. in Pathogenic Biology from the Chinese Academy of Medical Sciences and Peking Union Medical College, and a Bachelor's degree in Microbial Engineering from Shandong University. Dr. Liu has 30 years of experience in innovative vaccine R&D and industrialization. Before founding Recbio, he worked at the National Center for STD and AIDS Prevention and Control of the Chinese Center for Disease Control and Prevention for 10 years, serving as an associate researcher and researcher. During this period, he served as a visiting researcher at the Vaccine Research Center (VRC) of the National Institutes of Health (NIH) and the University of Maryland. He is currently the Chairman and CEO of Jiangsu Recbio Technology Co., Ltd., a member of the People's Congress of Taizhou City, Jiangsu Province, an executive director of the Jiangsu Association for the Promotion of Foreign Friendship and Exchanges, a director of the Jiangsu International Cultural Exchange Center, and the Vice President of the Pharmaceutical Industry Branch of the Shandong University Alumni Association.
![img](/media/p2thofbb/ellipse-13.png)
Executive Director and Chief Science Officer
![img](/media/p2thofbb/ellipse-13.png)
Executive Director and Chief Science Officer
Dr. Hong Kunxue is responsible for providing guidance and advice on R&D strategies of Recbio.
Dr. Hong holds a PhD in Genetics from Union Medical College, China, a Master's Degree in Clinical Laboratory Diagnostics from Jilin Medical College, China (now known as Beihua University), and a Bachelor's Degree in Clinical Medicine from Henan Medical University, China (now known as Zhengzhou University). Completed relevant postdoctoral research at the Chinese Center for Disease Control and Prevention. Dr. Hong has served as a research scholar at the University of California, Los Angeles, a leading academic institution in the United States, and as a visiting scholar at the Human Vaccine Institute of Duke University. He has more than 30 years of experience in immunology research at the Chinese Center for Disease Control and Prevention. He has worked at the Chinese CDC Center for STD and AIDS Prevention and Control for nearly 13 years and serves as a member of the Academic Committee and Degree Committee. Dr. Hong serves on the editorial board of "Infectious Microorganisms and Diseases (English)". Dr. Hong Kunxue has published more than 100 articles in academic journals in immunology and other related fields. Dr. Hong was awarded a Certificate of Honor for Fighting COVID-19 by the Hubei Provincial People's Government in April 2020. Dr. Hong was appointed as Optics Valley Industry Professor by Wuhan University in December 2021.
![img](/media/1vwcrqj5/ellipse-9.png)
Executive Director and Chief Human Resource Officer
![img](/media/1vwcrqj5/ellipse-9.png)
Executive Director and Chief Human Resource Officer
Mr. Li Bu is responsible for the daily operation and strategic development of Recbio human resources, IT, administration and procurement business.
Mr. Li Bu holds a master's degree in business administration from Kunming University and a bachelor's degree in technical economics from Central South University of Technology. He has more than 21 years of experience in human resources management. Before joining Recbio, Mr. Li Bu worked in human resources at Kunming Pharmaceutical Group Co., Ltd., served as assistant to the general manager of Yunnan Watson Biotechnology Co., Ltd., served as human resources director at Yunnan Belle Shoes Co., Ltd., and served as general manager at Kunming Hanyu Business Consulting Co., Ltd.
![img](/media/p3gdxwl1/ellipse-11.png)
Executive Director,CFO and Secretary of the Board
![img](/media/p3gdxwl1/ellipse-11.png)
Executive Director,CFO and Secretary of the Board
Ms. Chen Qingqing is responsible for Recbio corporate governance and capital operations, including finance, legal affairs, internal audit and internal control, and investor relations.
Ms. Chen Qingqing holds a master's degree in business administration from Peking University and a master's degree in economics from the Central University of Finance and Economics. She has more than 20 years of comprehensive financial management experience. Before joining Recbio, Ms. Chen Qingqing served as financial director, vice president and other senior financial executives in companies listed on the Hong Kong Stock Exchange and the New York Stock Exchange, such as Tencent, Renren, Beike and Qudian, and was responsible for the pre-IPO, IPO preparation and post-listing management of these companies.
![img](/media/jcjdqmar/ellipse-14.png)
Chief Quality Officer
![img](/media/jcjdqmar/ellipse-14.png)
Chief Quality Officer
Ms. Wang Jing is responsible for the overall quality management of Recbio.
Ms. Wang Jing holds a master's degree in bioengineering from Sichuan University and is a senior engineer. She has worked at the Chengdu Institute of Biological Products and has more than 20 years of experience in vaccine research and development, commercial production and quality management. She has nearly 10 years of experience as a manager of the quality management department and a quality authorized person in a vaccine manufacturer. She has rich experience in vaccine registration and has many successful registration cases. She is familiar with international/domestic GMP audit requirements and standards, has organized and passed WHO PQ on-site inspections and reviews several times, and is good at integrating ISO quality, environment and occupational health to meet the requirements of multiple standards GMP quality management system construction and operation.
![img](/media/m3rpzqz2/wechatimg1159.png)
Chief Technology Officer
![img](/media/m3rpzqz2/wechatimg1159.png)
Chief Technology Officer
Dr. Yang Kejian is responsible for the planning of the company's vaccine R&D strategy, the guidance and management of R&D projects, and external academic exchanges and cooperation.
Dr. Yang holds a Ph.D. in Science from the Chinese Academy of Preventive Medicine and a Bachelor's degree in Microbiology and Biochemistry from Hebei University. He completed postdoctoral research at the University of Massachusetts Medical School. He has 28 years of experience in developing preventive and therapeutic vaccines in American research institutions and biotechnology companies. He has engaged in the research and development of a variety of vaccines and adjuvants, and is good at mucosal immunity research and building mucosal vaccine delivery technology platforms. Before joining Recbio, he worked in R&D and management at Idera, Biomere and other companies in the United States. He is currently a visiting professor at Nanjing Medical University. He has published many influential articles and reviews, applied for more than 50 patents, and obtained nearly 30 authorized international patents.
![img](/media/xksepwko/20230508154548.png)
Chief Operating Officer
![img](/media/xksepwko/20230508154548.png)
Chief Operating Officer
Mr. Zhou Yang is responsible for the production, engineering, storage and transportation of Recbio. Mr. Zhou Yang holds a bachelor's degree in biotechnology from East China Normal University in Shanghai. Before joining Recbio, he served as deputy general manager of Sinopharm Chengdu Institute of Biological Products Co., Ltd. He has more than 20 years of experience in the vaccine industry and has rich professional and management experience in quality management, pharmacovigilance, storage and transportation, safety and environmental protection and other business areas.
![img](/media/cmbheifi/ellipse-16.png)
The finance director
![img](/media/cmbheifi/ellipse-16.png)
The finance director
Mr. Zhou Lei is responsible for the financial management and auditing of Recbio.
Mr. Zhou Lei holds a bachelor's degree in accounting from Jiangsu University of Science and Technology, and has obtained qualification certificates such as intermediate accountant, senior accountant, and certified tax accountant. Mr. Zhou has registered as a Chinese certified public accountant with the Chinese Institute of Certified Public Accountants. Mr. Zhou Lei has extensive professional experience in financial management and tax management of pharmaceutical companies. Before joining Recbio, he worked at Yangtze River Pharmaceutical Group Co., Ltd. as the financial director.
Awards & Certificates
Milestones
Recbio Enters a License and Strategic Cooperation with SPIMACO for the recombinant HPV-9 vaccine REC603
Completion Of The first batch of subject enrollment in the Phase I clinical trial of the new adjuvant recombinant herpes zoster vaccine in China
Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
Initiation Of Phase III Clinical Trial In China Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine Rec610
Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia
Acceptance Of Clinical Trial Application For Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio’s Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
Recbio signed a strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre
The Philippines has approved an international multicenter Phase II/III trial of the COVID-19 vaccine ReCOV
Recogen, a subsidiary specializing in the field of mRNA infectious vaccine, launched the world's first lyophilized dosage form mRNA vaccine
Successfully list on the main board of the Hong Kong Stock Exchange (SEHK) with stock code: 2179.HK
ReCOV Taizhou production base successfully passed THE EU QP audit
Phase II/III trial of ReCOV sequential booster immunization approved in UAE
Clinical Trial Approval For ReCOV In The PRC
Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines
Approval Of The Comparative Study Betweenrecov And mRNA Vaccines By FDA In The Philippines
Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine
Positive Results Of Multiple Overseas Phase II Clinical Trials Of Recombinant COVID-19 Vaccine ReCOV
Completion The First Batch Of Subject Enrollment For The International Multi-Center Phase III Clinical Trial Of Recombinant COVID-19 Vaccine ReCOV
Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In
The Philippines
Complete B+ round of financing and C round of financing
Launch Phase III clinical trial of recombinant nine-valent HPV vaccine (Hanson's yeast)
Launch Phase I clinical trial of recombinant COVID-19 vaccine in New Zealand
Recbio and Shenzhen Rhegen Biotechnology Co. Ltd. reached strategic cooperation and established a joint venture company Wuhan Recogen Biotechnology Co., Ltd. (Recogen) to jointly develop mRNA vaccine
Obtain the Drug Production License for COVID-19 vaccine issued by Jiangsu Food and Drug Administration.
Starte the construction of production facilities for the industrialization project of HPV vaccine
Complete Series B financing
Complete Phase I clinical trial of recombinant bivalent HPV16/18 vaccine (Hanson's yeast)
Complete Phase I clinical trial of recombinant nine-valent HPV vaccine (Hanson's yeast)
Start COVID-19 vaccine industrialization program
Launch Phase I clinical trial of recombinant nine-valent HPV vaccine (Hanson's yeast)
Complete Series A financing
Receive clinical trial approval for a recombinant bivalent HPV6/11 vaccine (Hanson's yeast)
Receive clinical trial approval for a recombinant nine-valent HPV vaccine (Hanson's yeast)
Receive clinical trial approval for a recombinant bivalent HPV16/18 vaccine (Hanson's yeast)
Launch research and development of recombinant herpes zoster vaccine and establishment of adjuvant platform
Establish and start operation in Taizhou China Pharmaceutical City Vaccine Engineering Center
Sign a Cooperation Agreement on HPV Preventive Vaccine (Recombinant Hanson's Yeast) with Beijing ABZYMO
Beijing ABZYMO Biosciences Co., Ltd. (the first operating entity of the company) was established
Collaborations